View Clinical Trial (Medical Research Study)

An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder - NCT00961298-15212(Clinical Trial 306278)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Pittsburgh
State:  
PA
Zip Code: 15212
Conditions: Irritable Bowel Syndrome - Generalized Anxiety Disorder
Purpose: The investigators propose to evaluate the effectiveness of duloxetine in treating subjects with both Irritable Bowel Syndrome (IBS) and Generalized Anxiety Disorder (GAD). The investigators hypothesize that duloxetine as a single therapeutic agent will effectively target pain and other core symptoms of IBS as well as GAD in this patient population with both conditions.
Study summary: Generalized Anxiety Disorder (GAD) is commonly associated with Irritable Bowel Syndrome(IBS). The etiology of IBS remains unknown and it is often refractory to treatment. Duloxetine has demonstrated efficacy in the treatment of GAD as well as other pain disorders including fibromyalgia and diabetic neuropathy. We plan to study 30 subjects with diagnoses of IBS and GAD between the ages of 18 and 65 years. There will be a single-blind placebo-run-in for the first 2 weeks, followed by open-label duloxetine for 12 weeks flexibly titrated to 120 mg/day. Subjects will be informed that they will receive placebo for 2 weeks during the trial. All study visits will be at Allegheny General Hospital Department of Psychiatry. The study consists of a total of nine office visits.
Criteria: Inclusion Criteria: - 18-65 years of age - Active IBS diagnosis by a gastroenterologist - Generalized Anxiety Disorder diagnosed by DSM-IV TR criteria and the Mini International Neuropsychiatric Interview for the DSM-IV (Mini) - No changes in any non study medication once starting the study Exclusion Criteria: - Current diagnoses of Major Depressive Disorder, Panic Disorder, Social Phobia, Post Traumatic Stress Disorder, Obsessive Compulsive Disorders, Eating Disorders, Somatoform Disorders, Drug or alcohol abuse or dependence, or severe personality disorder - Lifetime history of any Bipolar Disorder or Psychotic Disorder - Concurrent GI disorders falling outside of Rome III Functional GI disorders - Pregnant women or sexually active female subjects not using medically acceptable method of contraception - Current suicidal ideation - Unstable medical condition
Study is available at: Allegheny General Hospital
Pittsburgh, PA 15212
United States

Primary Contact:
Alicia J Kaplan, MD
Email: akaplan@wpahs.org
Phone: 412-330-4335

Secondary Contact:
Alicia J Kaplan, MD
Email: akaplan@wpahs.org
Phone: 412-330-4335
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.